379 related articles for article (PubMed ID: 28869699)
1. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
4. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
[TBL] [Abstract][Full Text] [Related]
7. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.
Sánchez-Delgado J; García-Iglesias P; Castro-Fernández M; Bory F; Barenys M; Bujanda L; Lisozain J; Calvo MM; Torra S; Gisbert JP; Calvet X
Aliment Pharmacol Ther; 2012 Jul; 36(2):190-6. PubMed ID: 22591220
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
Tepeš B; Vujasinović M; Šeruga M; Stefanovič M; Forte A; Jeverica S
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):676-83. PubMed ID: 26862930
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
Chuah SK; Liang CM; Lee CH; Chiou SS; Chiu YC; Hu ML; Wu KL; Lu LS; Chou YP; Chang KC; Kuo CH; Kuo CM; Hu TH; Tai WC
Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
[TBL] [Abstract][Full Text] [Related]
10. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
11. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
Campillo A; Amorena E; Ostiz M; Kutz M; LaIglesia M
Gastroenterol Hepatol; 2016 Nov; 39(9):584-589. PubMed ID: 27084668
[TBL] [Abstract][Full Text] [Related]
12. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Chen Q; Long X; Ji Y; Liang X; Li D; Gao H; Xu B; Liu M; Chen Y; Sun Y; Zhao Y; Xu G; Song Y; Yu L; Zhang W; Liu W; Graham DY; Lu H
Aliment Pharmacol Ther; 2019 Jun; 49(11):1385-1394. PubMed ID: 31020673
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial.
Zhang Y; Zhu YJ; Zhao Z; Zhao JT; Wang TY; Yang J; Chen DF; Lan CH
Eur J Gastroenterol Hepatol; 2020 May; 32(5):563-568. PubMed ID: 31851093
[TBL] [Abstract][Full Text] [Related]
15. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
[TBL] [Abstract][Full Text] [Related]
20. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.
Heo J; Jeon SW; Jung JT; Kwon JG; Lee DW; Kim HS; Yang CH; Park JB; Park KS; Cho KB; Lee SH; Jang BI;
J Gastroenterol Hepatol; 2015 Sep; 30(9):1361-6. PubMed ID: 25867608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
